The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic ...
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives ...
Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.
Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.
SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.
New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.
Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets ...
Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results